A treatment algorithm for children with lupus nephritis to prevent developing renal failure

Area of Science:

• Nephrology
• Rheumatology
• Immunology

Background:

• Chronic kidney disease (CKD) is a common complication of systemic lupus erythematosus (SLE).
• Lupus nephritis (LN) can progress to end-stage renal disease (ESRD) if untreated.
• Effective management of LN is critical for preserving kidney function.

Purpose of the Study:

• To outline current and emerging treatment strategies for lupus nephritis (LN).
• To present a new treatment algorithm for pediatric LN to prevent ESRD.
• To compare the efficacy and toxicity of different LN treatment regimens.

Main Methods:

• Review of current treatment protocols for active proliferative LN (Classes III and IV) and membranous LN (Class V).
• Comparison of intravenous methylprednisolone and mycophenolate mofetile (MMF) versus cyclophosphamide (CYC) therapy.
• Discussion of combination therapies including MMF with rituximab or calcineurin inhibitors for refractory cases.

Main Results:

• MMF combined with corticosteroids demonstrates efficacy and reduced toxicity for active proliferative LN compared to CYC.
• Both standard and shorter CYC courses followed by maintenance therapy with AZA or MMF are options for membranous LN.
• Combination therapies show promise for refractory LN.

Conclusions:

• Current treatment paradigms for LN have evolved, offering less toxic and more effective options.
• A new treatment algorithm is proposed for pediatric LN to prevent ESRD.
• Optimizing LN treatment is essential for long-term kidney health in SLE patients.